Ideeea TX on "Expansión": Ideeea TX secures €2.3 million in funding to address alopecia through stem cell-based therapy.

Biotech firm Ideeea TX raises €2.3 million to combat alopecia using stem cell therapy

The biotech company Ideeea Therapeutics has closed a €2.3 million seed funding round, supported by private investors and the Centre for the Development of Industrial Technology and Innovation (CDTI), within the framework of the Perte (Strategic Projects for Economic Recovery and Transformation), part of the European Union's Next Generation EU Recovery Plan, and funded through European instruments aimed at cutting-edge technologies.

The financing will accelerate the development of AGAcell, a product created by Ideeea. AGAcell is a preclinical research program exploring the intradermal administration of a patented stem cell formulation combined with a bioactive molecule, as a therapeutic approach to androgenetic alopecia.

According to the company, led by José Ángel Sánchez and Marisa Berenguer, "androgenetic alopecia goes beyond aesthetics, as the progressive loss of hair eliminates the natural protective barrier and chronically exposes the scalp to ultraviolet radiation, which is associated with increased photoaging and a higher risk of certain skin carcinomas."

Multiple studies have also highlighted its negative impact on self-esteem and mental health. To address this issue, AGAcell explores a potential therapy aimed at restoring the cellular microenvironment of the hair follicle to promote hair regeneration through a minimally invasive, non-surgical procedure. The program is also backed by the scientific leadership of Dr. Eduardo López Bran, a dermatologist specializing in trichology—the branch of dermatology focused on the study of hair and the scalp—and Head of the Dermatology Department at Hospital Clínico San Carlos in Madrid.

Open innovation approach

Ideeea Therapeutics follows an open innovation model, maintaining partnerships with hospitals and both public and private research centers. This allows the company to drive the development of its advanced therapy medicinal products (ATMPs), from research through to manufacturing under Good Manufacturing Practice (GMP) standards.

“At Ideeea Therapeutics, we are committed to evidence-based regenerative medicine that is accessible to society. With the AGAcell program, we are embarking on a path we believe will provide meaningful therapeutic alternatives to real clinical needs, always grounded in rigorous research and regulatory compliance,” says Marisa Berenguer, CEO of Ideeea Therapeutics.Read more: Expansión